![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Craig A. Vanstone D. Agrawal S.
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.7, Iss.10, 1997-10, pp. : 1175-1182
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Patent strategies for therapeutic RNAi
By Highlander Steven L Wohlers Travis M
Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 11, 2008-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Antisense oligonucleotide therapeutics
By Bennett C.F.
Expert Opinion on Investigational Drugs, Vol. 8, Iss. 3, 1999-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Antisense Anticancer Oligonucleotide Therapeutics
Current Cancer Drug Targets, Vol. 1, Iss. 3, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design, Vol. 10, Iss. 7, 2004-03 ,pp. :